BB Biotech’s Regeneron Pharmaceuticals REGN Stock Holding History

BB Biotech’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-68,156	Closed	-$25.5M	–	36
2018 Q4	$25.5M	Sell	68,156 -131,844	-66%	-$48.3M	0.82%	27
2018 Q3	$80.8M	Sell	200,000 -70,000	-26%	-$26.6M	2.14%	17
2018 Q2	$93.1M	Sell	270,000 -10,000	-4%	-$3.13M	2.69%	15
2018 Q1	$96.4M	Buy	280,000 +75,000	+37%	+$26.1M	2.66%	14
2017 Q4	$77.1M	Hold	205,000	–	–	2.17%	16
2017 Q3	$91.7M	Buy	205,000 +25,000	+14%	+$11.9M	2.54%	15
2017 Q2	$88.4M	Sell	180,000 -65,000	-27%	-$28.4M	2.7%	13
2017 Q1	$94.9M	Hold	245,000	–	–	3.11%	12
2016 Q4	$89.9M	Hold	245,000	–	–	3.33%	11
2016 Q3	$98.5M	Buy	245,000 +40,000	+20%	+$16M	3.46%	10
2016 Q2	$71.6M	Hold	205,000	–	–	2.83%	12
2016 Q1	$73.9M	Hold	205,000	–	–	2.94%	12
2015 Q4	$111M	Hold	205,000	–	–	3.13%	12
2015 Q3	$95.4M	Buy	205,000 +7,000	+4%	+$3.76M	3.02%	11
2015 Q2	$101M	Hold	198,000	–	–	2.74%	14
2015 Q1	$89.4M	Hold	198,000	–	–	2.66%	15
2014 Q4	$81.2M	Sell	198,000 -35,000	-15%	-$13.8M	2.63%	13
2014 Q3	$84M	Hold	233,000	–	–	3.42%	11
2014 Q2	$65.8M	Buy	233,000 +10,000	+4%	+$2.96M	3.13%	9
2014 Q1	$67M	Buy	223,000 +31,000	+16%	+$9.55M	3.45%	10
2013 Q4	$52.8M	Buy	192,000 +90,000	+88%	+$25.9M	2.82%	11
2013 Q3	$31.9M	Buy	+102,000	New	+$26.8M	1.74%	15

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech's REGN Position: Q1 2019 in Review

BB Biotech sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 68,156 shares — an estimated $25.5M sold.

BB Biotech first reported a position in REGN in Q3 2013 and held it in 22 quarters. The position peaked at $111M in Q4 2015. 719 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

BB Biotech reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
BB Biotech sold 68,156 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $25.5M.
BB Biotech first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 22 quarters.
BB Biotech's Regeneron Pharmaceuticals position peaked at $111M in Q4 2015.
719 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.